Loading…
Loading…
STAB does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for STAB and 80,000+ other tickers.
See exactly how STAB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for STAB and 80,000+ other tickers.
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies. These novel treatments aim to address a range of serious conditions, including autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. This development is underpinned by a proprietary technological platform engineered to restore the body's immune system balance and re-establish overall physiological homeostasis. The company's therapeutic strategies are designed to directly stimulate patients' immune systems, specifically eliciting…
24/06/26 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. CLARIANE SE Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 23/06/26 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
22/06/26 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Neopharmed Gentili S.p.A.
14/05/26 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. EGIS SA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 28/04/26 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
[14/05/2026] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [Biogroup] Post-stabilisation Period Announcement IF STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated [06/05/2026] and to the mid-stabilisation period announcement[s] dated [14/05/2026] BNP Paribas (contact: Stanford Hartman; telephone: 0207 595 8222) hereby gives notice that the Stabilisation Manager(s) named below undertook stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in relation to the offer of the following securities, as set out below.
14 May 2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. HOMEVI S.A.S Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 7th May 26 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.